The Food and Drug Administration and varenicline:should Risk Communication Be Improved? [PDF]
, 2016 [no ...
Davies, Neil M, Thomas, Kyla H
core +2 more sources
Characteristics of first-time varenicline users – A cross-sectional study in Finnish quitters
BMC Public Health, 2017 Background Varenicline is an efficacious medicine for smoking cessation (SC) but little is known about the characteristics of varenicline users. This study examined the characteristics of first-time (naïve) varenicline users in Finland and compared those
Hanna E. Tervonen +4 more
doaj +1 more source
Varenicline decreases nicotine but not alcohol self-administration in genetically selected Marchigian Sardinian alcohol-preferring (msP) rats [PDF]
, 2015 Background: Alcohol and nicotine are largely co-abused. Here, we investigated whether concurrent exposure to both addictive drugs influences each other's consumption and whether varenicline attenuates alcohol consumption in the presence of nicotine ...
Ciccocioppo, Roberto +4 more
core +1 more source
Implementation of a quality improvement project on smoking cessation reduces smoking in a high risk trauma patient population. [PDF]
, 2016 BackgroundCigarette smoking causes about one of every five deaths in the U.S. each year. In 2013 the prevalence of smoking in our institution's trauma population was 26.7 %, well above the national adult average of 18.1 % according to the CDC website. As
Carrens, Karen +5 more
core +1 more source
PLoS ONE, 2020 IntroductionVarenicline tartrate is superior for smoking cessation to other tobacco cessation therapies by 52 weeks, in the outpatient setting. We aimed to evaluate the long-term (104 week) efficacy following a standard course of inpatient-initiated ...
Kristin V Carson-Chahhoud +12 more
doaj +1 more source
The Economic Impact of Smoking and of Reducing Smoking Prevalence: Review of Evidence [PDF]
BACKGROUND: Tobacco smoking is the cause of many preventable diseases and premature deaths in the UK and around the world. It poses enormous health- and non-health-related costs to the affected individuals, employers, and the society at large.
Brown, AK, Ekpu, VU
core +1 more source
Prospective cohort study of the effectiveness of varenicline versus nicotine replacement therapy for smoking cessation in the "real world" [PDF]
, 2014 It is important to know the comparative effectiveness of varenicline and nicotine replacement therapy (NRT) for smoking cessation when prescribed under routine circumstances and in the general population. Previous estimates relied on cross-sectional data.
Brown, J, Kotz, D, West, R
core +1 more source
Integration of Tobacco Treatment Services into Cancer Care at Stanford. [PDF]
, 2020 As part of a National Cancer Institute Moonshot P30 Supplement, the Stanford Cancer Center piloted and integrated tobacco treatment into cancer care. This quality improvement (QI) project reports on the process from initial pilot to adoption within 14 ...
Fielding-Singh, Priya +7 more
core +2 more sources
Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review
Addiction, EarlyView.Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper +7 more
wiley +1 more source
Preventive Medicine Reports, 2015 Objectives: A recent trial showed the clinical benefit of retreatment with varenicline in subjects failing on the initial treatment, or relapsing after initial success.
Lieven Annemans +3 more
doaj +1 more source